GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: AJM-300 | AJM300 | Carogra®
carotegrast methyl is an approved drug
Compound class:
Synthetic organic
Comment: Carotegrast methyl (AJM300) is an orally administered esterified prodrug α4 integrin inhibitor/antagonist that was developed by EA Pharma for anti-inflammatory potential [1].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| AJM300 was advanced to Phase 3 clinical evaluation in patients with active ulcerative colitis (see NCT03531892). The safety and efficacy of AJM300 was first reported in 2015, with results from a Phase 2a study in Japan [5]. First approval was granted in Japan (March 2022) for the treatment of mesalazine-insensitive moderate ulcerative colitis. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03531892 | A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis | Phase 3 Interventional | Eisai Inc. | ||